HEALTHCARE PROVIDER ALERT July 6, 2021

To:



If you have any questions or concerns, please contact your local
Timiskaming Health Unit:

Monday to Friday 8:30 a.m. – 4:30 p.m.

New Liskeard

Tel: (705) 647-4305 Toll Free: (866) 747-4305 Fax: (705) 647-5779

Kirkland Lake

Tel: (705) 567-9355 Toll Free: (866) 967-9355 Fax: (705) 567-5476

After-Hours or Weekend On-Call Number (705) 647-3033

www.timiskaminghu.com

IMPORTANT UPDATES ON COVID-19

Physicians, Nurse Practitioners, Nurses, and Midwives
Hospital Infection Control Departments and Emergency Departments

Updated information on capillary leak syndrome and myocarditis/pericarditis are included in this alert.

The ministry has provided the following updates:

<u>June 29, 2021</u> - <u>Health Canada</u> / <u>French Version</u> updated the AstraZeneca and COVISHIELD Product Monographs and issued a Health Product Risk Communication. These updates highlight that capillary leak syndrome has been observed very rarely following vaccination with the AstraZeneca COVID-19 Vaccine, and provide further guidance for healthcare professionals and vaccine recipients.

In addition, information about thrombosis and thrombocytopenia (rare adverse reactions to the vaccine) has been updated on the label, recommending to healthcare professionals that individuals with thrombocytopenia following vaccination with the AstraZeneca COVID-19 vaccine should be investigated for signs of thrombosis, and similarly individuals who present with thrombosis should be investigated for thrombocytopenia. Health Canada continues to work closely with the manufacturer and international regulators to review data as it becomes available on these rare events. The Ministry of Health documents are being updated and will be posted shortly.

June 30, 2021 - Health Canada / French Version updated the Pfizer-BioNTech and Moderna Product Monographs to describe very rare reports of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination. Cases of myocarditis and/or pericarditis following immunization with COVID-19 vaccines have been reported in a small number of people in Canada and internationally. These reports are very rare and investigations into the association between myocarditis/pericarditis and mRNA vaccines continue. The Ministry of Health documents are being updated and will be posted shortly.

COVID-19 vaccines continue to be recommended